Neuroplasticity by Prescription: How Motivista Unlocks Negative Symptoms in Schizophrenia
Dr. Dereck Mush, MD, MBA
Click Therapeutics
Developer of prescription digital therapeutics, including Motivista for negative symptoms of schizophrenia.
What they do
Click Therapeutics received FDA 510(k) clearance in October 2026 for Motivista (CT-155), the first FDA-authorized treatment indicated specifically for negative symptoms of schizophrenia, used as an adjunct to clinician-managed care in adults. The clearance was supported by the Phase III CONVOKE study.
The record
- Vertical
- Mental & Behavioral Health
- Sub-segment
- Prescription digital therapeutics
- Product type
- Software as a medical device
- Stage
- Series D
- Headquarters
- New York, New York
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Notable investors: Boehringer Ingelheim.
Related on The Signal
Dr. Dereck Mush, MD, MBA
Medicare finally pays for prescription digital therapeutics, and the test begins
Dr. Dereck Mush, MD, MBA
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA